Person:
Griffiths, Anthony

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Griffiths

First Name

Anthony

Name

Griffiths, Anthony

Filters

20211

Settings

Author's Publications: search.filters.isAuthorOfPublication.ff05557d-79d2-47a0-abfb-45e3b07b6aa1

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    Structural Basis for Continued Antibody Evasion by the SARS-CoV-2 Receptor-Binding Domain
    (2021-12-02) Nabel, Katherine G.; Clark, Sarah A.; Shankar, Sundaresh; Pan, Junhua; Clark, Lars; Yang, Pan; Coscia, Adrian; McKay, Lindsay G.A.; Varnum, Haley; Brusic, Vesna; Tolan, Nicole V.; Zhou, Guohai; Desjardins, Michaël; Turbett, Sarah E.; Kanjilal, Sanjat; Sherman, Amy; Dighe, Anand; LaRocque, Regina C.; Ryan, Edward; Tylek, Casey; Cohen-Solal, Joel F.; Darcy, Andhao T.; Tavella, Davide; Clabbers, Anca; Fan, Yao; Griffiths, Anthony; Correia, Ivan R.; Seagal, Jane; Baden, Lindsey; Charles, Richelle; Abraham, Jonathan
    Many studies have examined the impact of SARS-CoV-2 variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor-binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.